Tachycardia, Atrioventricular Nodal Reentry

Biomedical engineers set the foundation for a ground-breaking treatment regimen for treating ventricular arrhythmia. The study demonstrates the design and feasibility of a new hydrogel-based pacing modality. The scientific advance is significant considering pain management is highly relevant to overall wellness for patients with heart, lung, and blood diseases. Such innovation in painless defibrillation and preventing arrhythmia could revolutionize cardiac rhythm management. A breakthrough study led by Dr. Mehdi Razavi at The Texas Heart Institute (THI), in collaboration with a biomedical engineering team of The University of Texas at Austin (UT Austin) Cockrell School of Engineering led by Dr. Elizabeth Cosgriff-Hernandez, sets the foundation of a ground-breaking treatment regimen for treating ventricular arrhythmia. Their study published in Nature Communications demonstrates the design and feasibility of a new hydrogel-based pacing modality. The urgent need for an effective therapeutic regimen for ventricular arrhythmia inspired THI's Electrophysiology Clinical Research & Innovations (EPCRI) team, led by its director, Dr. Razavi, to partner with Dr. Cosgriff-Hernandez and her UT Austin Biomedical Engineering (UT Austin BME) team to co-develop an innovative strategy that addresses the pathophysiology of re-entrant arrhythmia. Ventricular arrhythmia, which occurs in the lower chambers of the heart or ventricles, is the leading cause of sudden cardiac death in the United States. When heart rhythm abnormality occurs in a self-sustained manner, it is called re-entrant arrhythmia, which is usually fatal. "Re-entry occurs mainly from delayed conduction in scarred heart tissues, usually after coronary artery occlusion during a heart attack, which can be corrected by enabling pacing in these regions," said Dr. Razavi, a practicing cardiologist and cardiac electrophysiologist. "These hydrogels then can access the scarred tissue, thereby enabling direct pacing of the otherwise inaccessible regions of the heart." Given hydrogels' biostability, biocompatibility, tunable properties, and the ease of incorporating electrical conductivity, the scientists are exploring them as potential electrodes that can be easily delivered inside coronary veins. A clinical advantage of the unique system is that ischemia can be avoided by delivering the hydrogel using the veins. The researchers successfully deployed the innovative hydrogel technology through minimally invasive catheter delivery in a pig model. "The hydrogels have significant conductive properties that enable simultaneous pacing from multiple sites along the length of the hydrogel and create a conduction highway similar to those in Purkinje fibers," according to Dr. Cosgriff-Hernandez. Today, arrhythmia is treatable with medicines and procedures that control the irregular rhythms. The current anti-arrhythmic drugs on the market are not always effective; although the drugs slow the conduction velocity, they facilitate re-entry arrhythmia. Moreover, these drugs can be toxic and can lead to the destruction of tissues near the diseased regions of the heart. Even with the widely used interventional ablation therapies, arrhythmia recurs in a significant proportion of patients. None of these procedures address the mechanism of re-entry. Cardiac defibrillators implanted to compensate for the shortfalls in the current therapy options are painful when delivering electric shocks to restore heart rhythm and can severely deteriorate the patient's quality of life. If left untreated, arrhythmia can damage the heart, brain, or other organs, leading to stroke or cardiac arrest, during which the heart suddenly and unexpectedly stops beating. "When injected into target vessels, the conductive hydrogel conforms to the patient's vessel morphology. Adding a traditional pacemaker to this gel allows for pacing that resembles the native conduction in the heart -- effectively mimicking the native electrical rhythm of the heart -- and extinguishes the cause for arrhythmia, providing painless defibrillation," added Dr. Cosgriff-Hernandez. The work demonstrates for the first time the ability to confer direct electrical stimulation of the native and scarred mid-myocardium through injectable hydrogel electrodes as a pacing modality. With minimally invasive catheter delivery and standard pacemaker technologies, this study indicates the feasibility of a novel pacing modality that resembles native conduction, potentially eliminating lethal re-entrant arrhythmia and providing painless defibrillation, which can be successfully adopted in a clinical workflow. The scientific advance is significant considering pain management is highly relevant to overall wellness for patients with heart, lung, and blood diseases. Such innovation in painless defibrillation and preventing arrhythmia could revolutionize cardiac rhythm management. Funding was provided by the National Heart, Lung, and Blood Institute of the National Institutes of Health (R01 HL162741); Ford Pre-Doctoral Fellowship, administered by the National Academy of Science, Engineering and Medicine; Ford Dissertation Fellowship, administered by the National Academy of Science, Engineering and Medicine; Office of Vice President for Research, The University of Texas at Austin; The Roderick D. MacDonald Research Fund Award 19RDM004; and The Sultan Qaboos Chair in Cardiology at the St. Luke's Foundation.

NEW YORK, June 8, 2022 /PRNewswire/ -- According to the market research report published by P&S Intelligence, the global electrophysiology market is on the path to generating $17,482.7 million by 2030, compared to $7,076.1 million in 2021, advancing at a compound annual growth rate of 10.6% between 2021 and 2030. The growing count of cardiac ablation procedures, rising reforms for healthcare infrastructure growth, increasing demand for ablation and diagnostic catheters, and technology advancements are some major aspects driving the growth of the market. Ablation Catheters Category Generated Highest Revenue Ablation catheters had the biggest share of the market in 2021, and the category size is expected to increase at a significant rate, of 10.9%, from 2021 to 2030. Ablation is a non-invasive procedure in which catheters are used to remove faulty electrical pathways in the heart that create cardiac arrhythmia. Furthermore, in 2021, laboratory devices accounted for a 31.4% share of the electrophysiology market. This was due to the growing public and private funding for the development of new electrophysiology recording systems in both developed and developing countries. Moreover, the market for RF ablation treatments is growing because of the rising frequency of these treatments, their cost-effectiveness when compared to other ablation methods, and the easy accessibility of laboratory devices. Get the sample pages of this report at: Electrophysiology solutions are most commonly used in hospitals and cardiac centers. As a result, in 2021, the category had the largest share in the market, and it is predicted to grow at a 10.6% CAGR over the forecast period. This will be owing to an increase in the footfall at electrophysiology and catheterization labs, as well as in the count of ablation treatments performed in both public and private hospitals across the world. Geographical Analysis of Electrophysiology Market The APAC electrophysiology market is expected to advance at an 11.0% CAGR during the forecast period. China has the largest share in the APAC region owing to the rising heart disease, obesity, stress, and other chronic disease prevalence, as a result of the changing lifestyles and eating habits and growing trend of drinking and smoking. In 2021, North America dominated the market, and it is predicted to remain dominant in the future. This is because of the surging count of approvals for electrophysiology devices, increasing cases of cardiac arrhythmias, rising demand for cardiac ablation procedures, and existence of major companies in the region. Browse detailed report on Global Electrophysiology Market Size, Growth Drivers and Demand Forecast To 2030 The European electrophysiology market is dominated by Germany. Electrophysiology devices are expected to become more popular as the cases of cardiovascular diseases rise in the country. Furthermore, the growing private and government investments in the healthcare sector are likely to fuel the market expansion in the near future. Electrophysiology Device Advancements Are Propelling Market Growth Depending on how they are used to treat cardiac arrhythmias, new electrophysiological devices could have better success rates. Treatment options for cardiac arrhythmias have altered as a result of the technological advancements, thus decreasing the incidence of adverse cardiac events. Improvements in electrophysiology include irrigation RF ablation catheters and improved cryoablation procedures. Electrophysiology Market Segmentation Analysis By Product Type Ablation Catheters Laboratory Devices Diagnostic Catheters Access Devices By Indication Atrial Fibrillation Atrial Flutter Atrioventricular Nodal Reentry Tachycardia (AVNRT) Wolff-Parkinson-White Syndrome (WPW) By End Users Hospitals and Cardiac centers Ambulatory Surgery Centers Regional Outlook North America U.S. Canada Europe U.K. Germany France Spain Italy Asia-Pacific China India Japan South Korea Australia Latin America Brazil Mexico Middle East and Africa Saudi Arabia South Africa Browse Other Reports Published by P&S Global Catheters and Bands Market Size, Share, Growth, and Demand Forecast Report Global Catheter Market Size, Share, Growth, and Demand Forecast Report Global Peripheral I.V. Catheter Market Size, Share, Growth, and Demand Forecast Report Global Robotic Catheter Systems Market Size, Share, Growth, and Demand Forecast Report About P&S Intelligence P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies. Contact: Prajneesh Kumar P&S Intelligence Phone: +1-347-960-6455 Email: [email protected] Web: Follow Us: LinkedIn Twitter SOURCE P&S Intelligence

OTTAWA, June 25, 2021 (GLOBE NEWSWIRE) -- The global electrophysiology devices market was valued at US$ 5.54 billion in 2019. The Electrophysiology (EP) study aids in the assessment of electrical impulses of the heart as well as to evaluate abnormal heartbeats. In addition, the prominent advancement in the electrophysiology technologies has improved the ability to focus the areas of the heart perpetuating that causes to atrial fibrillation (AF). The increasing development has enhanced the treatment and diagnosis of other cardiac arrhythmias too that include atrioventricular nodal reentry tachycardia (AVNRT), Wolff-Parkinson-White Syndrome (WPW), atrial flutter, and others. Get the Sample Pages of Report for More Understanding@ Growth Factors As the prevalence of cardiac arrhythmia is constantly increasing on the global level, electrophysiology devices accounted for substantial recognition in the forthcoming years. Distinctive modalities of electrophysiology devices that include cardiac magnetic resonance imaging (CMR), cardiac computerized tomography (CT), echocardiography, fluoroscopy, and electro-anatomic mapping; support healthcare professionals to prodigiously analyze the principal mechanisms of multiple cases of arrhythmia. In addition, worldwide penetration of electrophysiology devices is likely to encounter a tectonic upshift by the year 2027 because of remarkable technological disruption in the healthcare industry. The strategic expansion plans of market participants remains aligned toward matured markets that are already consolidated by the significant presence of large companies. While matured markets will continue to provide substantial revenue-generating opportunities for aspiring brands in the global electrophysiology devices market, evolving markets are likely to promise alluring opportunities for these brands to increase their sales revenues. Report Highlights Get Customization on this Research Report@ Regional Snapshots In 2019, North America led the global electrophysiology devices market owing to unhealthy lifestyle oriented such as smoking and excessive alcohol consumption leads to increased rate of cardiac arrest cases, Heart Failure (HF), and cardiac arrhythmia. Presence of sophisticated healthcare infrastructure and favorable policies for reimbursement propels the growth of electrophysiology devices in the region. On the other side, the electrophysiology market in the Asia Pacific, particularly in Japan, China, and India expected to register high growth in the forthcoming years. India and China are the most lucrative regions compared to other Asian countries because of rapidly changing eating habits and lifestyles, increasing stress, fast adoption of western culture, and habitual drinking and smoking in these countries have resulted in the increasing health-related problems that include heart disease, obesity, and other chronic diseases. Factors such as increasing geriatric population, large population, rising healthcare spending, growing incidence of chronic diseases, rising emphasis of prominent players on emerging markets, increasing demand for advanced technologies, healthcare reforms for infrastructural development, and less stringent regulations related to consumption of alcohol and other disease triggering products fuel the demand for electrophysiology devices in this region. Related Reports Key Players & Strategies The global electrophysiology devices market is highly competitive with increased focus of market players on new product development along with extensive investment on Research & Development (R&D) as a part of sustainability strategy. These industry participants also follow inorganic growth strategies to establish a strong footprint in the market coupled with extended range of product portfolio, thereby enhancing their brand recognition. For instance, in July 2018, Boston Scientific Corporation acquired Cryterion Medical, Inc., a privately held firm focused developing treatment for atrial fibrillation (AF) using its single-shot cryoablation platform. The acquisition helped the company to have a diverse product portfolio for electrophysiology devices. Similarly, in November 2018, Boston Scientific Corporation acquired BTG plc, a UK based company that involved in the commercialization and development of minimally invasive surgical (MIS) products for vascular diseases and cancer. Some of the key players operating in the market are Medtronic Plc, Abbot Laboratories, Boston Scientific Corporation, Biotronik SE & CO. KG, Biosense Webster, Inc., Nihon Kohden Corporation, GE Healthcare, Microport Scientific Corporation, Siemens AG, and Koninklijke Philips N.V. among others. Market Segmentation By Indication By Application By End-User By Regional Outlook Buy this Premium Research Report@ You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us: